Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells

Cell Death and Disease

Volumn 6, Issue 3, 2015, Pages

  Fitzgerald, A L ^a,b   Osman, A A ^b   Xie, T X ^b   Patel, A ^b   Skinner, H ^b   Sandulache, V ^c   Myers, J N ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ARTICLE; CANCER CELL; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SENESCENCE; SIGNAL TRANSDUCTION; CELL AGING; GENETICS; HEAD AND NECK TUMOR; IMMUNOBLOTTING; IONIZING RADIATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RADIATION RESPONSE; TUMOR CELL LINE;

CELL AGING; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HEAD AND NECK NEOPLASMS; HUMANS; HYDROGEN PEROXIDE; IMMUNOBLOTTING; OXIDATIVE STRESS; PHOSPHORYLATION; RADIATION, IONIZING; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84989948049     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.44     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res 2011; 17: 2035-2043.
3. Skvortsov S, Jimenez CR, Knol JC, Eichberger P, Schiestl B, Debbage P et al. Radioresistant head and neck squamous cell carcinoma cells: intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiother Oncol 2011; 101: 177-182.
4. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154-1157.
5. Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010; 28: 761-766.
6. Slovackova J, Smarda J, Smardova J. Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53. Neoplasma 2012; 59: 606-612.
7. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000; 18: 1465-1473.
8. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355.
9. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998; 16: 1671-1679.
10. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-2561.
11. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
12. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000; 20: 3224-3233.
13. Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E et al. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 1997; 36: 10117-10124.
14. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 325-334.
15. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
16. Neskey DM, Osman AA, Ow TJ, Katsonis P, Mcconald T, Hicks S et al. Evolutionary Action score of TP53 coding variants (EAp53) identifies high risk mutations associated with decreased survival and increased development of distant metastases in head and neck cancer. J Clin Oncol 2015; e-pub ahead of print 29 January 2015.
17. Lichtarge O, Bourne HR, Cohen FE. An evolutionary trace method defines binding surfaces common to protein families. J Mol Biol 1996; 257: 342-358.
18. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
19. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997; 277: 831-834.
20. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-98.
21. Vogt M, Haggblom C, Yeargin J, Christiansen-Weber T, Haas M. Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. Cell Growth Differ 1998; 9: 139-146.
22. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994; 371: 534-537.
23. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
24. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
25. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998; 9: 585-593.
26. Masgras I, Carrera S, de Verdier PJ, Brennan P, Majid A, Makhtar W et al. Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. J Biol Chem 2012; 287: 9845-9854.
27. Gadhikar MA, Sciuto MR, Alves MV, Pickering CR, Osman AA, Neskey DM et al. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 2013; 12: 1860-1873.
28. Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci USA 1995; 92: 4337-4341.
29. Barzilai A, Yamamoto K. DNA damage responses to oxidative stress. DNA Repair 2004; 3: 1109-1115.
30. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiationinduced senescence. Clin Cancer Res 2012; 18: 290-300.
31. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129-1133.
32. Sandulache VC, Skinner HD, Ow TJ, Zhang A, Xia X, Luchak JM et al. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer 2012; 118: 711-721.
33. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
34. Qian Y, Chen X. Tumor suppression by p53: making cells senescent. Histol Histopathol 2010; 25: 515-526.
35. Chang BD, Watanabe K, Broude EV, Fang J, Poole JC, Kalinichenko TV et al. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci USA 2000; 97: 4291-4296.
36. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 2009; 34: 663-673.
37. Macip S, Igarashi M, Fang L, Chen A, Pan ZQ, Lee SW et al. Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J 2002; 21: 2180-2188.
38. Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R, Poole JC et al. p21Waf1/ Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene 2000; 19: 2165-2170.
39. Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 2011; 13: 561-569.
40. Zhou G, Xie TX, Zhao M, Jasser SA, Younes MN, Sano D et al. Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene 2008; 27: 3527-3538.
41. Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004; 64: 7977-7984.
42. Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flowcytometry. Methods Mol Biol 2010; 594: 57-72.
43. He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR et al. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer 2006; 95: 1514-1524.